In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Elevated HDL-C is associated with adverse cardiovascular outcomes
2018

Congress : ESC Congress

  • Topic : preventive cardiology
  • Sub-topic : Lipids, Other
  • Session type : Advances in Science
  • FP Number : 50

Authors : M Allard-Ratick (Atlanta,US), J Khambhati (Atlanta,US), M Topel (Atlanta,US), P Sandesara (Atlanta,US), L Sperling (Atlanta,US), A Quyyumi (Atlanta,US)

15 views

Authors:
M. Allard-Ratick1 , J. Khambhati1 , M. Topel1 , P. Sandesara1 , L. Sperling1 , A. Quyyumi1 , 1Emory University, Cardiology - Atlanta - United States of America ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 3

Background: Previous studies have shown reduced cardiovascular (CV) risk with increasing high-density lipoprotein cholesterol (HDL-C) levels. However, at elevated HDL-C levels (>60mg/dl), its atheroprotective functions, such as cholesterol efflux and anti-oxidant capacity, may be impaired. The association between high levels of HDL-C and adverse outcomes remains unclear.

Purpose: To study the relationship between elevated HDL-C levels (>60mg/dl) and adverse CV outcomes in an at-risk population.

Methods: Participants included 5,965 individuals (mean age 63.3±12.4 years, 35% female, 23% African American) enrolled in the cardiovascular biobank. Restricted cubic spline curves were used to examine the potential non-linear association between HDL-C and adverse outcomes using HDL-C of 50mg/dL as reference. Individuals were also stratified by HDL-C categories (<30, 31–40, 41–50, 51–60 and ≥60 mg/dL) and a Cox proportional hazards model was used to examine the association between HDL-C and adverse outcomes, with HDL-C 51–60 mg/dL as the reference group. All models were adjusted for age, race, sex, body mass index, hypertension, smoking, triglycerides, low density lipoprotein cholesterol, heart failure history, myocardial infarction (MI) history, diabetes, angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker use, beta blocker use, statin use, aspirin use, estimated glomerular filtration rate, obstructive coronary artery disease.

Results: Over a median follow-up of 3.9 years (interquartile range 1.6 to 6.6 years), there were 769 CV death/non-fatal MI events. Restricted cubic spline regression models demonstrated a “U-shaped” association between HDL-C and CV death/non-fatal MI (Figure 1) and all-cause mortality (not pictured). Individuals with HDL-C <30 mg/dL (n=825) and ≥60 mg/dL (n=570) had an increased risk of all-cause mortality and CV death/non-fatal MI (HR 1.62; 95% CI=1.16–2.26, p=0.005 and HR 1.44; 95% CI = 1.01–2.06, p=0.04 respectively) after adjusting for aforementioned variables.

Conclusion: Elevated HDL-C levels are paradoxically associated with an increased risk of adverse CV events in an at-risk population, suggesting dysfunctional HDL and impaired atheroprotection.

Association of HDL-C and CV death/MI

Please login to My ESC

This content may be restricted, please sign in to check your access.

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are